Literature DB >> 27498060

Overexpression of DIXDC1 correlates with enhanced cell growth and poor prognosis in human pancreatic ductal adenocarcinoma.

Xiaohong Li1, Ying Xiao2, Shaoqing Fan3, Mingbing Xiao3, Xiaotong Wang3, Xiaolin Zhu2, Xudong Chen4, Chunsun Li4, Guijuan Zong4, Guoxiong Zhou5, Chunhua Wan6.   

Abstract

Disheveled-axin (DIX) domain containing 1 (DIXDC1), a protein containing a coiled-coil domain and a DIX domain, is involved in the progression of multiple cancers. However, the role of DIXDC1 in human pancreatic ductal adenocarcinoma (PDAC) remains unclear. In this study, we investigated the role and prognostic value of DIXDC1 in the development of human PDAC. Western blot analysis revealed that DIXDC1 was highly expressed in PDAC tissues and cell lines. Immunohistochemistry on 165 paraffin-embedded sections showed that high expression of DIXDC1 was significantly correlated with tumor size (P = .002), histological differentiation (P = .001), tumor node metastasis (TNM) stage (P = .001), and the proliferation marker Ki-67 (P = .000). Importantly, Kaplan-Meier analysis revealed that high expression of DIXDC1 was obviously correlated with worsened overall survival (P < .001). In vitro, using serum starvation-refeeding experiments, our results suggested that DIXDC1 was up-regulated in proliferating PDAC cells, together with the percentage of cells at the S phase, and was correlated with the expression of cyclin D1. In addition, depletion of DIXDC1 decreased PCNA and cyclin D1 levels. Accordingly, CCK-8, colony formation, and flow cytometry analyses revealed that knocking down DIXDC1 induced growth impairment and G1/S cell cycle arrest in PDAC cells, while overexpression of DIXDC1 led to accelerated cell proliferation and cell cycle progression. On the basis of these results, we propose that DIXDC1 could play an important role in the tumorigenesis of PDAC and serve as a potential therapeutical target to prevent PDAC progression.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cell cycle progression; Cell proliferation; DIXDC1; Pancreatic ductal adenocarcinoma; Prognosis

Mesh:

Substances:

Year:  2016        PMID: 27498060     DOI: 10.1016/j.humpath.2016.07.015

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  6 in total

1.  Suppression of Disheveled-Axin Domain Containing 1 (DIXDC1) by MicroRNA-186 Inhibits the Proliferation and Invasion of Retinoblastoma Cells.

Authors:  Xuanyi Che; Yuanjie Qian; Di Li
Journal:  J Mol Neurosci       Date:  2017-12-20       Impact factor: 3.444

2.  Overexpression and biological function of MEF2D in human pancreatic cancer.

Authors:  Zhiwang Song; Chan Feng; Yonglin Lu; Yong Gao; Yun Lin; Chunyan Dong
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

3.  MicroRNA-154 Inhibits the Growth and Invasion of Gastric Cancer Cells by Targeting DIXDC1/WNT Signaling.

Authors:  Jifu Song; Zhibin Guan; Maojiang Li; Sha Sha; Chao Song; Zhiwei Gao; Yongli Zhao
Journal:  Oncol Res       Date:  2017-08-11       Impact factor: 5.574

4.  Circular RNA circ_0000423 promotes gastric cancer cell proliferation, migration and invasion via the microR-582-3p/Disheveled-Axin domain containing 1 axis.

Authors:  Chao-Qun Huang; Ping Yang; Jiuyang Liu; Yin-Ping Wang; Dan-Dan Hao; Xiaojun Yang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

5.  DIX domain containing 1 (DIXDC1) modulates VEGFR2 level in vasculatures to regulate embryonic and postnatal retina angiogenesis.

Authors:  Yeaji Kim; Dong Young Kim; Haiying Zhang; Cho-Rong Bae; Daehyeon Seong; Yeomyung Kim; Jaewhan Song; Young-Myeong Kim; Young-Guen Kwon
Journal:  BMC Biol       Date:  2022-02-10       Impact factor: 7.431

6.  SERP1 is a novel marker of poor prognosis in pancreatic ductal adenocarcinoma patients via anti-apoptosis and regulating SRPRB/NF-κB axis.

Authors:  Qiang Ma; Xiuxiu Wu; Jing Wu; Zhiyong Liang; Tonghua Liu
Journal:  Int J Oncol       Date:  2017-08-31       Impact factor: 5.650

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.